Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 101–200 of 999
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
Koh, B., Xiao, J., Ng, C. H., Law, M., Gunalan, S. Z., Danpanichkul, P., Ramadoss, V., Sim, B., Tan, E. Y., Teo, C. B., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001028 · Cited by 33
Self-citationAlkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Jackson, E., Dennis, A., Alkhouri, N., Samala, N. R., Vuppalanchi, R., Sanyal, A. J., Muthiah, M. D., Banerjee, R., & Banerjee, A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03654-2 · Cited by 31
Self-citationThe expanding benefits of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102214 · Cited by 42
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Self-citationZhang, G. Y., & Brandman, D. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.6431 · Cited by 27
Kamrul-Hasan, A. B. M., Alam, M. S., Dutta, D., Sasikanth, T., Aalpona, F. T. Z., & Nagendra, L. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2164 · Cited by 27
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
Zhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Self-citationRinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 34
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Ou, Y., Cui, Z., Lou, S., Zhu, C., Chen, J., Zhou, L., Zhao, R., Wang, L., & Zou, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1463657 · Cited by 32
Castañé, H., Jiménez-Franco, A., Hernández‐Aguilera, A., Martínez-Navidad, C., Cambra-Cortés, V., Onoiu, A.-I., Jiménez-Aguilar, J. M., París, M., Hernández, M., Parada, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105532 · Cited by 34
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 36
Romanos, M., Cordova, J. M. G., Villamarin, J. L., Zurita, J. D. P., & Acosta, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70659 · Cited by 34
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Metabolic dysfunction–associated steatotic liver disease and pregnancy
Sarkar, M., & Kushner, T. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186426 · Cited by 37
Liu, H., Lefere, S., Guillot, A., Zheng, M., & Tacke, F. (2025) · Hepatology · doi:10.1097/hep.0000000000001417 · Cited by 43
Recompensation in decompensated cirrhosis
Premkumar, M., Kamath, P. S., Reiberger, T., & Reddy, K. R. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00095-0 · Cited by 37
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
Shumbayawonda, E., French, M., Carolan, J. E., Beyer, C., Lorgelly, P. K., Tonev, D., Banerjee, R., Miller, M. H., Byrne, C. D., Patel, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00796-9 · Cited by 25
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 31
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass
Va, I. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i20.105346 · Cited by 29
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
Lazarus, J. V., Brennan, P., Mark, H. E., Alazawi, W., Allen, A. M., Byrne, C. D., Castéra, L., Caussy, C., Cusi, K. J., Grajower, M. M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101320 · Cited by 34
Goto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 30
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Elshaer, A., Chascsa, D. M. H., & Lizaola‐Mayo, B. (2024) · Life · doi:10.3390/life14070844 · Cited by 32
Gastaldelli, A., & Newsome, P. N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf094 · Cited by 29
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1096 · Cited by 36
Vignera, S. L., Cannarella, R., Garofalo, V., Crafa, A., Barbagallo, F., Condorelli, R. A., & Calogero, A. E. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01425-9 · Cited by 36
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 32
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
Microbiome−mediated crosstalk between T2DM and MASLD: a translational review focused on function
Jing, M., & Jiang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1677175 · Cited by 24
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Corrao, S., Calvo, L., Granà, W., Scibetta, S., Mirarchi, L., Amodeo, S., Falcone, F., & Argano, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.07.019 · Cited by 30
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Yang, Z., Liu, Z., Liu, W., & Dong, X. C. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100218 · Cited by 33
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 27
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
Moncho, F., Benlloch, S., & Górriz, J. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf260 · Cited by 26
Genetic and non-genetic drivers of histological progression and regression in MASLD
Gómez, E. V., Yates, K. P., Kleiner, D. E., Behling, C. A., Cummings, O. W., Wilson, L., Liang, T., Jarasvaraparn, C., Loomba, R., Schwimmer, J. B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.013 · Cited by 29
Self-citationCaussy, C., Cusi, K. J., Rosenstock, J., Bugianesi, E., Thomas, M. K., Tang, Y., Mather, K. J., Loomba, R., Sanyal, A. J., & Hartman, M. L. (2025) · Diabetes Care · doi:10.2337/dc25-1306 · Cited by 32
Self-citationSelective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 32
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
Liver and obesity: a narrative review
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001334 · Cited by 23
Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19
Screening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 20
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 26
Gurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 19
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 26
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 27
Gao, Y., Li, C., Chang, W., Du, B., Ye, X., Yeo, Y. H., Xia, Y., Guo, H., Zhang, X., Liu, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68414-3 · Cited by 30
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
Zhang, A., Liu, Q., Xiong, Y., Li, J., Xu, Y., Song, H., Jing, X., Xu, H., Yang, N., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16294 · Cited by 22
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Call to action—Pediatric MASLD requires immediate attention to curb health crisis
Hartmann, P., Mouzaki, M., Hassan, S. M., Kehar, M., Mysore, K. R., Mauney, E. E., Nonga, D., Karjoo, S., Sood, S., Tou, A. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001440 · Cited by 20
Self-citationIncretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Chen, L., Horn, P., & Tacke, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70545 · Cited by 23
Update in clinical science: MASLD in children and adolescents
Lefere, S., Koot, B. G. P., Mann, J. P., Bufler, P., Bruyne, R. D., & Hudert, C. A. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.02.016 · Cited by 21
GLP-1 agonists and exercise: the future of lifestyle prioritization
Codella, R., Senesi, P., & Luzi, L. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1720794 · Cited by 16
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
Shantaram, D., Rima, X. Y., Bradley, D. P., Liu, J. Z., Wright, V. P., AMARI, A., Jalilvand, A., Rottinghaus, J., Fernandes, J. M., Smith, A. J., et al. (2025) · Diabetes · doi:10.2337/db24-0861 · Cited by 18
Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
Betlejewska, J., Hubska, J., Roszkowska, Z., Maciejczyk, A., Bachurska, D., Domański, J., Miarka, M., Raszeja‐Wyszomirska, J., Bobrowicz, M., & Ambroziak, U. (2025) · Biomedicines · doi:10.3390/biomedicines13102500 · Cited by 20
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
Wen, S., Zhang, H., Huang, X., Wang, C., Dong, M., Wang, C., Xu, C., Yuan, Y., Li, Y., Zhou, L., et al. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s517874 · Cited by 19
Luu, S., Chan, D. E. C. Y., Marshall, N. S., Phillips, C. L., Grunstein, R. R., & Yee, B. J. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102169 · Cited by 17
Savino, A., Loglio, A., Neri, F., Camagni, S., PASULO, L., Lucà, M. G., Trevisan, R., FAGIUOLI, S., & Viganò, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133871 · Cited by 15
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 20
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Browne, S., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Georges, B., Roberts, M. S., & Harris, M. S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101483 · Cited by 18
Ajmera, V. H., Vuppalanchi, R., Khalili, M., Sheikh, M. Y., Risser, J. A., Klein, S., Tincopa, M. A., Madamba, E. V., Singh, S., Siddiqi, H., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70516 · Cited by 17
Self-citationQiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.